Late Initiation of HAART Among HIV-Infected Patients in Spain Is Frequent and Related to a Higher Rate of Virological Failure but not to Immigrant Status

REFERENCES

• Chadborn TR, Baster K, Delpech VC, et al. No time to wait: how many HIV-infected homosexual men are diag-nosed late and consequently die? (England and Wales, 1993-2002). AIDS. 2005;19(5):513–520.
   PubMed Web of Science ®Google Scholar
• Chadborn TR, Delpech VC, Sabin CA, Sinka K, Evans BG. The late diagnosis and consequent short-term mor-tality of HIV-infected heterosexuals (England and Wales, 2000-2004). AIDS. 2006;20(18):2371–2379.
   PubMed Web of Science ®Google Scholar
• Delpierre C, Lauwers-Cances V, Pugliese P, et al. Char-acteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people. Eur J Public Health. 2008;18(3):345–347.
   PubMed Web of Science ®Google Scholar
• Lanoy E, Mary-Krause M, Tattevin P, et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther 2007;12(1):89–96.
   PubMed Web of Science ®Google Scholar
• Sobrino-Vegas P, Garcia-San Miguel L, Caro-Murillo AM, et al. Delayed diagnosis of HIV infection in a multicenter cohort: prevalence, risk factors, response to HAART and impact on mortality. Curr HIV Res. 2009;7(2): 224–230.
   PubMed Web of Science ®Google Scholar
• Boyd AE, Murad S, O'Shea S, de Ruiter A, Watson C, Easterbrook PJ. Ethnic differences in stage of presentation of adults newly diagnosed with HIV-1 infection in south London. HIV Med. 2005;6(2):59–65.
   PubMed Web of Science ®Google Scholar
• Nellen JF, Wit FW, De Wolf F, Jurriaans S, Lange JM, Prins JM. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and nonindig-enous HIV-1-infected patients in the Netherlands. J Acquir Immune Defic Syndr 2004;36(4):943–950.
   PubMed Web of Science ®Google Scholar
• Burns FM, Imrie JY, Nazroo J, Johnson AM, Fenton KA. Why the(y) wait? Key informant understandings of factors contributing to late presentation and poor utilization of HIV health and social care services by African migrants in Britain. AIDS Care. 2007;19(1):102–108.
   PubMed Web of Science ®Google Scholar
• Fakoya I, Reynolds R, Caswell G, Shiripinda I. Barriers to HIV testing for migrant black Africans in Western Europe. HIV Med. 2008;9 (Suppl 2):23–25.
   PubMed Web of Science ®Google Scholar
• Tedaldi EM, Absalon J, Thomas AJ, Shlay JO, van den Berg-Wolf M. Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiret-roviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr 2008;47(4):441–448.
   PubMed Web of Science ®Google Scholar
• Dray-Spira R, Spire B, Heard I, Lert F. Heterogeneous response to HAART across a diverse population of people living with HIV: results from the ANRS-EN12-VESPA Study. AIDS. 2007;21(Suppl 1):55–12.
   Web of Science ®Google Scholar
• Lanoy E, Mary-Krause M, Tattevin P, et al. Predictors identified for losses to follow-up among HIV-seropositive patients. J Clin EpidemioL 2006;59(8):829–835.
   PubMed Web of Science ®Google Scholar
• Navaza B, Navarro M, Guionnet A, Perez-Molina J, Lopez-Velez R. Africa, blood, and HIV: overcoming cultural bar-riers regarding HIV blood testing. XVII International AIDS Conference; August 3–8, 2008; Mexico City, Mexico.
   Google Scholar
• Stohr W, Back D, Dunn D, et al. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antivir Ther. 2008;13(5): 675–685.
   PubMed Web of Science ®Google Scholar
• Martinez-Cajas JL, Pai NP, Klein MB, Wainberg MA. Differ-ences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008). J Int AIDS Soc. 2009;12(1):11.
   PubMed Web of Science ®Google Scholar
• Egger M. Outcomes of ART in resource-limited and indus-trialized countries. Paper presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25–28, 2007; Los Angeles, CA, USA.
   Google Scholar
• Krentz HB, Auld MC, Gill MJ. The high cost of medical care for patients who present late (CD4 <200 cells/microL) with HIV infection. HIV Med. 2004;5(2):93–98.
   PubMed Web of Science ®Google Scholar
• Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327)119–129.
   Web of Science ®Google Scholar
• Mussini C, Manzardo C, Johnson M, et al. Patients pre-senting with AIDS in the HAART era: a collaborative cohort analysis. AIDS. 2008;22(18):2461–2469.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Gatell J, Landman R, Antinori A. Manage-ment of late-presenting patients with HIV infection. Antivir Ther 2010;15(Suppl 1):25–30.
   PubMed Web of Science ®Google Scholar
• Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. AIDS. 2006;20(10):1447–1450.
   PubMed Web of Science ®Google Scholar
• Pérez-Molina J, Mora M, Suarez-Lozano I, et al. Do HIV-infected immigrants initiating HAART have poorer treat-ment- related outcomes than autochthonous patients in Spain? Results of the GESIDA 5808 Study. Curr HIV Res. 2010;8(7):521–530.
   PubMed Web of Science ®Google Scholar
• Gazzard BG, Anderson J, Babiker A, et al. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9(8):563–608.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services. Panel on Anti-retroviral Guidelines for Adults and Adolescents: guidelines for the use of antiretrovirals agents in HIV-1-infected adults and adolescents. Updated December 1,2009. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed May 10,2010.
   Google Scholar
• Street E, Curtis H, Sabin CA, Monteiro EF, Johnson MA. British HIV Association (BHIVA) national cohort outcomes audit of patients commencing antiretrovirals from naive. HIV Med. 2009;10(6):337–342.
   PubMed Web of Science ®Google Scholar
• Johnson M, Sabin C, Girardi E. Definition and epide-miology of late presentation in Europe. Antivir Ther. 2010;15(Suppl 1):3–8.
   PubMed Web of Science ®Google Scholar
• Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/rito-navir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372(9639):646–655.
   PubMed Web of Science ®Google Scholar
• Ortiz R, Dejesus E, Khanlou H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS. 2008;22(12):1389–1397.
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med. 2009;361(23):2230–2240.
   PubMed Web of Science ®Google Scholar
• Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921–929.
   PubMed Web of Science ®Google Scholar